Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical's H-Shares Surge to All-Time High

05/03/2021 | 04:32am EDT

By Clarence Leong

Shanghai Fosun Pharmaceutical (Group) Co.'s Hong Kong-listed shares soared as much as 20% on Monday, touching an all-time high of HK$59.45.

The surge mirrored its A-shares, which jumped 10% on both Wednesday and Friday, following its first-quarter results.

The company's first-quarter operating income advanced 37% from a year earlier to 8.06 billion yuan ($1.24 billion), while net profit rose 47% to CNY847.2 million, thanks to growth in drug sales, as well as a low-base effect as the company was hit by the Covid-19 pandemic last year.

Its A-shares last traded at CNY60.24, outperforming its peers with a 51% gain for the month of April. In contrast, Jiangsu Hengrui Medicine Co.'s share price fell 8.7% last month, while Guangzhou Baiyunshan Pharmaceutical Holdings Co. rose 10%. The mainland China market was closed Monday for a holiday.

Bocom International said the results were in line with its expectations, and that the company's pharmaceutical segment could maintain a double-digit compound annual growth rate, partly thanks to the expanded hospital sales channel for innovative drugs.

The company distributes the Covid-19 vaccines developed by BioNTech SE in the Greater China region.

Its shares were most recently up 19.45% at HK$58.95.

Write to Clarence Leong at clarence.leong@wsj.com

(END) Dow Jones Newswires

05-03-21 0431ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 5.04% 328.35 Delayed Quote.302.78%
DJ INDUSTRIAL -0.42% 34935.47 Delayed Quote.14.63%
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED -1.64% 21 End-of-day quote.10.41%
JIANGSU HENGRUI MEDICINE CO., LTD. -1.32% 54.38 End-of-day quote.-41.45%
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 9.54% 81.88 End-of-day quote.51.66%
UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH) -0.01% 6.46373 Delayed Quote.-0.47%
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
07/28SHANGHAI FOSUN PHARMACEUTICAL : An announcement has just been published by the i..
PU
07/19Sisram Medical Seeks $80 Million in Private Placement; Shares Fall 6%
MT
07/19SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement entering into the placing..
PU
07/19SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Ex-dividend day for final dividend
FA
07/14SINOVAC BIOTECH : Fosun-BioNTech COVID-19 vaccine completes China regulator revi..
RE
07/14MARKET CHATTER : BioNTech's COVID-19 Vaccine Advances to Administration Review i..
MT
07/14SHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolution proposed at the 2..
PU
07/13Hong Kong says no personal data shared in vaccine deal with Fosun
RE
07/13Sisram Medical Limited completed the acquisition of Shanghai Foshion Medical ..
CI
07/12Politics, health collided in Taiwan's tortured BioNTech vaccine talks
RE
More news
Financials
Sales 2021 40 184 M 6 220 M 6 220 M
Net income 2021 4 372 M 677 M 677 M
Net Debt 2021 15 917 M 2 464 M 2 464 M
P/E ratio 2021 48,2x
Yield 2021 0,63%
Capitalization 165 B 25 482 M 25 485 M
EV / Sales 2021 4,49x
EV / Sales 2022 3,98x
Nbr of Employees 32 258
Free-Float 58,8%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 81,88 CNY
Average target price 57,08 CNY
Spread / Average Target -30,3%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman